Respiratory Tract Infections

Clinical Trial Reinforces Safety of Tequin Antibiotic

Published in Drug Week, October 6th, 2000

The results of the Tequin Clinical Experience Study (TeqCES), the largest clinical study of community-acquired respiratory tract infections (RTIs) conducted for an antibiotic, were announced during the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Toronto, Canada, during September 2000.

The study enrolled more than 15,000 patients who were treated with Tequin (gatifloxacin), the quinolone antibiotic marketed by Bristol-Myers Squibb. The objective of the study was to validate the efficacy and safety of Tequin in the community setting.

"In the community setting, respiratory infections are usually treated empirically, and...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Week

Source: Drug Week (2000-10-06)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry